



Cancer Research

Latest Update 01/05/2026

Cancer

- **LSU LCMC Health Cancer Center**, Innovative and Catalytic Cancer Research ([ICCR](#)) Program. The Pilot Program is designed to support short-term, cancer-relevant projects with strong potential to lead to external funding, high-impact publications, new collaborations, and other outcomes that advance the scientific priorities of the Cancer Center. Projects across the full research spectrum, basic, translational, clinical, and population science, are encouraged.
 - Letters of Intent submission open: **February 2**
 - Letters of Intent due: **February 20**
 - Application open: **March 9**
 - Full proposal due: **April 24**
 - Award notifications: **Early June**
 - Project start date: **July 1**
 - The program is open to all Full LSU LCMC Health Cancer Center Members, and it strongly encourages multi-PI and cross-campus collaborations
 - Once launched, application will be submitted through InfoReady. Additional details will be available when the InfoReady portal opens.

- The **Henry & Marilyn Taub Foundation**, [2026 MDS Pilot Research Grants](#) for early-career investigators. To foster innovation and the expansion of MDS research, collaborative efforts with those from non-MDS fields are encouraged.
 - Letter of Intent Deadline: **March 9, 2026**
 - Full Applications are Invited: **April 15, 2026**
 - Full Application Deadline: **July 1, 2026**
 - Award Notification: **September 26, 2026**
 - Funding Start: **December 1, 2026**
- **NCI**, Toward Translation of Nanotechnology Cancer Interventions (TTNCI; **R01** Clinical Trial Not Allowed) ([PAR-25-336](#)). **Expiration Date: November 16, 2027.**
- **NCI**, Innovative Research in Cancer Nanotechnology (IRCN; **R01** Clinical Trial Not Allowed) ([PAR-25-106](#)). **Expiration Date: May 05, 2026.**
- **NCI**, Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (**R01** Clinical Trial Optional) ([PAR-25-175](#)). **Expiration Date: January 08, 2028.**
- **NCI**, NIAAA, Population Approaches to Reducing Alcohol-related Cancer Risk (**R01** Clinical Trial Optional) ([PAR-25-221](#)). **Expiration Date: January 08, 2027.**
- **NCI**, Cancer Prevention and Control Clinical Trials Grant Program (**R01** Clinical Trial Required) ([PAR-25-167](#)). **Expiration Date: January 08, 2027.**
- **NCI**, Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (**R01** Clinical Trial Not Allowed) ([PAR-24-304](#)). **Expiration Date: October 15, 2026.**
- **NCI**, National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (**R01** Clinical Trial Required) ([PAR-25-081](#)). **Expiration Date: January 08, 2027.**

- **NCI, Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)** ([PA-25-172](#)). **Expiration Date: January 08, 2028.**
- **NCI, Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)** ([PAR-24-311](#)). **Expiration Date: January 08, 2028.**
- **NCI, Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)** [PAR-25-043](#), **(R21 Clinical Trial Not Allowed)** [PAR-25-044](#). **Expiration Date: January 08, 2028.**
- **NIH, Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)** ([PAR-25-095](#)); **(R21 Clinical Trials Not Allowed)** ([PAR-25-096](#)). **Expiration Date: September 08, 2026.**
- **NCI, Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)** ([PAR-25-069](#)); **(R21 Clinical Trial Not Allowed)** ([PAR-25-070](#)). **Expiration Date: January 08, 2027.**
- **NCI, Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)** ([PA-25-253](#)). **Expiration Date: September 08, 2028.**
- **NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)** ([PA-25-304](#)). **Expiration Date: January 8, 2028.**
- **NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)** ([PA-25-306](#)). **Expiration Date: January 8, 2028.**
- **NCI, Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)** ([PAR-25-103](#)); **(R34 Clinical Trials Optional)** ([PAR-25-104](#)). **Expiration Date: October 26, 2027.**
- **NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)** ([PAR-25-135](#)). **Expiration Date: October 15, 2027.**
- **NCI, Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)** ([PAR-25-074](#)), **(UH3 Clinical Trials Not Allowed)** ([PAR-25-075](#)). **Expiration Date: October 15, 2026.**
- **AACR, American Association for Cancer Research Funding Opportunities.**
[Details.](#)

- [AACR Non-Small Cell Lung Cancer Research Fellowship](#)
 - Letter of Intent Deadline: January 22, 2026
 - Application Deadline: May 7, 2026
- [AACR-Torrey Coast Foundation Transpacific Gastric and Esophageal Cancer Research Partnership Grant](#)
 - Application Deadline: January 15, 2026
- [AACR Maximizing Opportunity for New Advancements in Research in Cancer \(MONARCA\) Grant for Latin America](#)
 - Letter of Intent Deadline: January 22, 2026
 - Application Deadline: May 14, 2026